Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Trial in Adult Subjects With Spinocerebellar Ataxia
      Description

      The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

      Conditions
      Spinocerebellar AtaxiasSpinocerebellar Ataxia Genotype Type 1Spinocerebellar Ataxia Genotype Type 2Spinocerebellar Ataxia Genotype Type 3Spinocerebellar Ataxia Genotype Type 6Spinocerebellar Ataxia Genotype Type 7Spinocerebellar Ataxia Genotype Type 8Spinocerebellar Ataxia Genotype Type 10
      Talk to us
      UNKNOWN
      Genetic Mechanism of Conserved Ancestral Haplotype in SCA10
      Description

      Spinocerebellar ataxia type 10 (SCA10) is a hereditary ataxia whose ancestral mutation occurred in East Asia. The mutation is likely to have migrated during peopling of American continents from East Asia. We found a specific rare DNA variation associated with SCA10. We test whether this variation played a key role in the birth and subsequent spreading of SCA10 mutation.

      Conditions
      Spinocerebellar Ataxia Type 10
      Talk to us